Search 

The Pharmaceutical Licensing Group, in the UK, has been established for 30 years and is the professional association for those active in pharmaceutical and biotechnology business development and licensing. 

There are around 200 members in the UK and over a 1000 in affiliated groups in Europe, Canada and Japan. All sectors of the industry are represented including multinationals, medium and small pharmaceutical companies, biotechnology, generic and consumer companies. 

The PLG is a not-for-profit organisation and is managed by a committee of licensing and business development executives from member companies. Details of the Committee members and how to contact them can be found by following the Committee link. 

The PLG organises meetings within local countries, a bi-annual European meeting and a bi-annual International meeting. Details of all meetings can be found on the Events page and by linking to other PLG sites on the European page. 

Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists they work with their clients to answer their R&D questions and de-risk drug development.

Pictura Bio’s groundbreaking diagnostic platform was born out of a unique combination of medical and technical expertise in virology, biophysics and microscopy from the company’s co-founders, Dr Nicole Robb and Nicolas Shiaelis.

Poolbeg Pharma plc (AIM: POLB) is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. 

Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.

Contact Precision for Medicine, Oncology and Rare Disease via their website

Research Donors collects, processes and delivers human blood biospecimens that meet the most demanding research requirements. With a diverse community of over 4000 healthy donors, we can meet any donor specification as required by your project.

We collect fresh HLA typed leukopaks, PBMCs, whole blood and other blood derivatives from donors who have been serologically screened and provided full consent for their samples to be used in commercial and genetic research. Delivery is same day of collection (in certain parts of UK) or next day of collection across the rest of UK and Europe. Soon, we will also be able to procure disease biospecimens.

Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges. 

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.